As a leader in cell‑free DNA manufacturing, Touchlight is shaping the next era of advanced therapy development. At ASGCT, our team will discuss how mbDNA™ and Custom Circles, our next‑generation, circular single‑stranded DNA formats, enable developers to move faster, overcome plasmid constraints, and streamline the path from discovery to clinic.

Throughout the meeting, our commercial and scientific experts will be onsite for discussions so if you’re attending ASGCT, we welcome you to connect with us to explore how Touchlight’s technology can accelerate your pipeline.